How this company measures up on the fundamentals that matter
Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, the company offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI-enabled Test Selection, a generative AI-enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. The company has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics. The company was founded in 1995 and is headquartered in Burlington, North Carolina.
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Trading at $254 against a fair value of $389, a 35% discount. Fails ethical screen (Debt ratio). Ranks better than 69% of screened stocks.
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Trading characteristics and market positioning
Balance sheet strength and cash generation — the foundation of long-term value
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-11 | SCHECHTER ADAM H | Chief Executive Officer | 5,903 | $1,502,314 | |
| 2026-03-27 | WILKINSON PETER J | Officer | 1,633 | $436,093 | |
| 2026-03-27 | MELTZER JONATHAN C | Officer | 839 | $224,055 | |
| 2026-03-26 | KYLE KATHRYN W | Officer | 1,584 | — | |
| 2026-03-26 | VAUGHN BRYAN T | Officer | 1,584 | — | |
| 2026-03-26 | VAN DER VAART SANDRA DILLARD | Officer | 6,382 | — | |
| 2026-03-26 | CAVENEY BRIAN J | Officer | 11,290 | — | |
| 2026-03-26 | SCHROEDER MARK S | Chief Operating Officer | 12,272 | — | |
| 2026-03-26 | SUMMY AMY B | Officer | 3,994 | — | |
| 2026-03-26 | BAILEY MEGAN D | Officer | 1,184 | — |
Congressional trading disclosures involving this instrument
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 7 Feb2025 | Tim Walberg | Republican | buy | 15K–50K |
Data sourced from public filings and market feeds. Not financial advice. Updated: 2025-12-31